GSK-3β Inhibitor CHIR-99021 Promotes Proliferation Through Upregulating β-Catenin in Neonatal Atrial Human Cardiomyocytes. Issue 6 (December 2016)
- Record Type:
- Journal Article
- Title:
- GSK-3β Inhibitor CHIR-99021 Promotes Proliferation Through Upregulating β-Catenin in Neonatal Atrial Human Cardiomyocytes. Issue 6 (December 2016)
- Main Title:
- GSK-3β Inhibitor CHIR-99021 Promotes Proliferation Through Upregulating β-Catenin in Neonatal Atrial Human Cardiomyocytes
- Authors:
- Wang, Shoubao
Ye, Lincai
Li, Minghui
Liu, Jinfen
Jiang, Chuan
Hong, Haifa
Zhu, Hongbin
Sun, Yanjun - Abstract:
- Abstract : Background: The renewal capacity of neonate human cardiomyocytes provides an opportunity to manipulate endogenous cardiogenic mechanisms for supplementing the loss of cardiomyocytes caused by myocardial infarction or other cardiac diseases. GSK-3β inhibitors have been recently shown to promote cardiomyocyte proliferation in rats and mice, thus may be ideal candidates for inducing human cardiomyocyte proliferation. Methods: Human cardiomyocytes were isolated from right atrial specimens obtained during routine surgery for ventricle septal defect and cultured with either GSK-3β inhibitor (CHIR-99021) or β-catenin inhibitor (IWR-1). Immunocytochemistry was performed to visualize 5-ethynyl-2′-deoxyuridine (EdU)–positive or Ki67-positive cardiomyocytes, indicative of proliferative cardiomyocytes. Results: GSK-3β inhibitor significantly increased β-catenin accumulation in cell nucleus, whereas β-catenin inhibitor significantly reduced β-catenin accumulation in cell plasma. In parallel, GSK-3β inhibitor increased EdU-positive and Ki67-positive cardiomyocytes, whereas β-catenin inhibitor decreased EdU-positive and Ki67-positive cardiomyocytes. Conclusions: These results indicate that GSK-3β inhibitor can promote human atrial cardiomyocyte proliferation. Although it remains to be determined whether the observations in atrial myocytes could be directly applicable to ventricular myocytes, the current findings imply that Wnt/β-catenin pathway may be a valuable pathway forAbstract : Background: The renewal capacity of neonate human cardiomyocytes provides an opportunity to manipulate endogenous cardiogenic mechanisms for supplementing the loss of cardiomyocytes caused by myocardial infarction or other cardiac diseases. GSK-3β inhibitors have been recently shown to promote cardiomyocyte proliferation in rats and mice, thus may be ideal candidates for inducing human cardiomyocyte proliferation. Methods: Human cardiomyocytes were isolated from right atrial specimens obtained during routine surgery for ventricle septal defect and cultured with either GSK-3β inhibitor (CHIR-99021) or β-catenin inhibitor (IWR-1). Immunocytochemistry was performed to visualize 5-ethynyl-2′-deoxyuridine (EdU)–positive or Ki67-positive cardiomyocytes, indicative of proliferative cardiomyocytes. Results: GSK-3β inhibitor significantly increased β-catenin accumulation in cell nucleus, whereas β-catenin inhibitor significantly reduced β-catenin accumulation in cell plasma. In parallel, GSK-3β inhibitor increased EdU-positive and Ki67-positive cardiomyocytes, whereas β-catenin inhibitor decreased EdU-positive and Ki67-positive cardiomyocytes. Conclusions: These results indicate that GSK-3β inhibitor can promote human atrial cardiomyocyte proliferation. Although it remains to be determined whether the observations in atrial myocytes could be directly applicable to ventricular myocytes, the current findings imply that Wnt/β-catenin pathway may be a valuable pathway for manipulating endogenous human heart regeneration. … (more)
- Is Part Of:
- Journal of cardiovascular pharmacology. Volume 68:Issue 6(2016)
- Journal:
- Journal of cardiovascular pharmacology
- Issue:
- Volume 68:Issue 6(2016)
- Issue Display:
- Volume 68, Issue 6 (2016)
- Year:
- 2016
- Volume:
- 68
- Issue:
- 6
- Issue Sort Value:
- 2016-0068-0006-0000
- Page Start:
- 425
- Page End:
- 432
- Publication Date:
- 2016-12
- Subjects:
- β-catenin -- cardiomyocytes -- CHIR-99021 -- proliferation
Cardiovascular Diseases -- drug therapy -- Periodicals
Cardiovascular System -- drug effects -- Periodicals
Cardiovascular pharmacology -- Periodicals
Cardiovascular agents -- Periodicals
Cardiovascular agents
Cardiovascular pharmacology
Periodicals
615.7105 - Journal URLs:
- http://journals.lww.com/cardiovascularpharm/pages/default.aspx ↗
http://www.cardiovascularpharm.com ↗
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=toc&D=yrovft&AN=00005344-000000000-00000 ↗
http://journals.lww.com ↗ - DOI:
- 10.1097/FJC.0000000000000429 ↗
- Languages:
- English
- ISSNs:
- 0160-2446
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4954.868000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 8245.xml